Arthur Kuan is recorded as CEO at CG Oncology, Inc. (CGON). The newest filing on record that lists Arthur Kuan as CEO at CG Oncology, Inc. (CGON) is dated April 24, 2026. CG Oncology, Inc. reported in an 8-K filed May 26, 2026 that Arthur Kuan was appointed President, effective May 20, 2026. The proxy statement of CG Oncology, Inc. reports total compensation of $11,928,401 for Arthur Kuan in fiscal 2025, including a base salary of $690,000. Disclosed compensation is on record for 3 fiscal years. Arthur Kuan has spoken on 4 investor events across 1 company, most recently for CG Oncology, Inc. on September 14, 2026. CG Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at CG Oncology, Inc. includes Corleen M. Roche (CFO), Jim DeTore (CFO), Ambaw Bellete (COO) and 4 others.
“On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.”
CG Oncology, Inc. Form 8-K, filed May 26, 2026
· Read the filing
Arthur Kuan on recent calls
“Yeah, certainly, based on what we've seen coming out of China, it is something to be respected, and I don't think we should take it lightly. So more broadly, I think we think a lot about when it comes to U.S. innovation, what is the competitive advantage?”
“So we're a company that's laser focused on developing our oncolytic immunotherapy, for patients with both intermediate risk as well as high risk non-muscle invasive bladder And we have a number of catalysts coming up.”
“This is a setting in the U.S. that we believe could address up to 150,000 patients. And so we've been solely focused on this, and we believe cretosimaging can really make a huge impact in this specific segment.”
“Many of you know we've initiated our role, and this is in the BCG unresponsive. So that's one of the key highlights of narrowing that guidance. And the second update, you know, the guidance remains the same that the first half of this year are top line data from the PIVOT6 trial.”
